Related Experiment Video

Updated: Sep 11, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 28, 2014

17.1K

Nivolumab in renal cell carcinoma: latest evidence and clinical potential

Camille Mazza1, Bernard Escudier2, Laurence Albiges3

  • 1Department of Medical Oncology, Gustave Roussy, Villejuif, France.

Therapeutic Advances in Medical Oncology
|March 28, 2017
PubMed

Insights

Nivolumab, a PD-1 inhibitor, offers a new treatment for renal cell carcinoma (RCC) by restoring the immune system's ability to fight cancer. This review covers its effectiveness and future potential in RCC therapy.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Renal cell carcinoma (RCC) was historically treated with interleukin 2 (IL-2) and interferon alpha (IFN-α), showing limited efficacy (10-20%) and poor tolerability.
  • The programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway is crucial in tumor immune evasion.

Purpose of the Study:

  • To review the clinical data and experience with nivolumab, a PD-1 inhibitor, in the treatment of renal cell carcinoma (RCC).
  • To discuss the current clinical experience and future directions for nivolumab therapy in RCC.

Main Methods:

  • Review of studies investigating nivolumab in RCC.
  • Analysis of clinical experience with nivolumab for RCC treatment.

Main Results:

  • Nivolumab is an approved PD-1 inhibitor for various cancers, including RCC.
  • This review discusses the efficacy and clinical application of nivolumab in RCC.

Conclusions:

  • Immune checkpoint blockade, specifically targeting the PD-1/PD-L1 pathway, represents a significant advancement in cancer immunotherapy.
  • Nivolumab demonstrates potential in treating RCC by enhancing anti-tumor immune responses.
Keywords:
immune checkpoint inhibitorimmunotherapynivolumabprogrammed death-1renal cell carcinoma

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 11, 2017

14.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 21, 2019

12.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...